Ex vivo gene transfer using adenovirus-mediated full-length dystrophin delivery to dystrophic muscles

[1]  E. Hoffman,et al.  Muscle maturation: implications for gene therapy. , 1998, Molecular medicine today.

[2]  J. Tremblay,et al.  Transplantation of myoblasts from a transgenic mouse overexpressing dystrophin produced only a relatively small increase of dystrophin‐positive membrane , 1998, Muscle & nerve.

[3]  I. Kovesdi,et al.  Myoblast-Mediated Ex Vivo Gene Transfer to Mature Muscle , 1997 .

[4]  S. Kochanek,et al.  Persistence in muscle of an adenoviral vector that lacks all viral genes. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[5]  Simon C Watkins,et al.  LacZ gene transfer to skeletal muscle using a replication-defective herpes simplex virus type 1 mutant vector. , 1997, Human gene therapy.

[6]  J. Wilson,et al.  Immunology of gene therapy with adenoviral vectors in mouse skeletal muscle. , 1996, Human molecular genetics.

[7]  Simon C Watkins,et al.  The basal lamina is a physical barrier to herpes simplex virus-mediated gene delivery to mature muscle fibers , 1996, Journal of virology.

[8]  K. Campbell,et al.  In vivo muscle gene transfer of full-length dystrophin with an adenoviral vector that lacks all viral genes. , 1996, Gene therapy.

[9]  R. Balice-Gordon,et al.  In vivo expression of full-length human dystrophin from adenoviral vectors deleted of all viral genes. , 1996, Human gene therapy.

[10]  M. Grounds,et al.  Rapid death of injected myoblasts in myoblast transfer therapy , 1996, Muscle & nerve.

[11]  J. Chamberlain,et al.  Encapsidated adenovirus minichromosomes allow delivery and expression of a 14 kb dystrophin cDNA to muscle cells. , 1996, Human molecular genetics.

[12]  C. Caskey,et al.  A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[13]  Hanns Lochmüller,et al.  Dystrophin expression in muscles of mdx mice after adenovirus-mediated in vivo gene transfer. , 1996, Human gene therapy.

[14]  I. Kinoshita,et al.  Successful histocompatible myoblast transplantation in dystrophin- deficient mdx mouse despite the production of antibodies against dystrophin , 1995, The Journal of cell biology.

[15]  C. Gravel,et al.  FK506 immunosuppression to control the immune reactions triggered by first-generation adenovirus-mediated gene transfer. , 1995, Human gene therapy.

[16]  S. Noguchi,et al.  Dystrophin-associated proteins in muscular dystrophy. , 1995, Human molecular genetics.

[17]  J. Glorioso,et al.  Herpes simplex virus type 1 vector mediated gene transfer to muscle. , 1995, Gene therapy.

[18]  N. Sarvetnick,et al.  Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[19]  R. Roy,et al.  Very efficient myoblast allotransplantation in mice under FK506 immunosuppression , 1994, Muscle & nerve.

[20]  N. Emi,et al.  Humoral and cellular immunity to an encoded protein induced by direct DNA injection. , 1994, Human gene therapy.

[21]  I. Nonaka,et al.  Selective defect of sarcoglycan complex in severe childhood autosomal recessive muscular dystrophy muscle. , 1994, Biochemical and biophysical research communications.

[22]  Hanns Lochmüller,et al.  Cultured human myoblasts and myotubes show markedly different transducibility by replication-defective adenovirus recombinants. , 1994, Gene therapy.

[23]  G. Acsadi,et al.  Gene transfer into skeletal muscles by isogenic myoblasts. , 1994, Human gene therapy.

[24]  J. Wilson,et al.  Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[25]  H. Yamamoto,et al.  Dissociation of the complex of dystrophin and its associated proteins into several unique groups by n-octyl beta-D-glucoside. , 1994, European journal of biochemistry.

[26]  E. Furth,et al.  Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[27]  M. Noble,et al.  Myogenic cell lines derived from transgenic mice carrying a thermolabile T antigen: a model system for the derivation of tissue-specific and mutation-specific cell lines. , 1994, Developmental biology.

[28]  G. Acsadi,et al.  A differential efficiency of adenovirus-mediated in vivo gene transfer into skeletal muscle cells of different maturity. , 1994, Human molecular genetics.

[29]  J. Huard,et al.  Human myoblast transplantation in immunodeficient and immunosuppressed mice: Evidence of rejection , 1994, Muscle & nerve.

[30]  K. Campbell,et al.  Dystrophin–glycoprotein complex: Its role in the molecular pathogenesis of muscular dystrophies , 1994, Muscle & nerve.

[31]  B. Trapnell,et al.  Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice , 1993, Nature Genetics.

[32]  P. Tonali,et al.  Retroviral vector-mediated gene transfer into human primary myogenic cells leads to expression in muscle fibers in vivo. , 1993, Human gene therapy.

[33]  M. Perricaudet,et al.  Long–term correction of mouse dystrophic degeneration by adenovirus–mediated transfer of a minidystrophin gene , 1993, Nature genetics.

[34]  J. Huard,et al.  Use of fluorescent latex microspheres (FLMs) to follow the fate of transplanted myoblasts. , 1993, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[35]  K. Campbell,et al.  Overexpression of dystrophin in transgenic mdx mice eliminates dystrophic symptoms without toxicity , 1993, Nature.

[36]  George Karpati,et al.  Myoblast transfer in duchenne muscular dystrophy , 1993, Annals of neurology.

[37]  F. Walsh,et al.  Direct retroviral-mediated transfer of a dystrophin minigene into mdx mouse muscle in vivo. , 1993, Human molecular genetics.

[38]  P. Briand,et al.  Efficient adenovirus-mediated transfer of a human minidystrophin gene to skeletal muscle of mdx mice , 1993, Nature.

[39]  J. Ervasti,et al.  Association of dystrophin-related protein with dystrophin-associated proteins in mdx mouse muscle , 1992, Nature.

[40]  C. Richards,et al.  Human myoblast transplantation between immunohistocompatible donors and recipients produces immune reactions. , 1992, Transplantation proceedings.

[41]  G. Acsadi,et al.  Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle. , 1992, Human molecular genetics.

[42]  S. Hauschka,et al.  Transient neonatal denervation alters the proliferative capacity of myosatellite cells in dystrophic (129ReJdy/dy) muscle. , 1992, Journal of neurobiology.

[43]  J. Bouchard,et al.  Human myoblast transplantation: Preliminary results of 4 cases , 1992, Muscle & nerve.

[44]  H. Blau,et al.  Normal dystrophin transcripts detected in Duchenne muscular dystrophy patients after myoblast transplantation , 1992, Nature.

[45]  O. Ibraghimov-Beskrovnaya,et al.  Primary structure of dystrophin-associated glycoproteins linking dystrophin to the extracellular matrix , 1992, Nature.

[46]  K. Davies,et al.  Retroviral‐mediated transfer of a dystrophin minigene into mdx mouse myoblasts in vitro , 1992, FEBS letters.

[47]  J. Ervasti,et al.  Membrane organization of the dystrophin-glycoprotein complex , 1991, Cell.

[48]  K. Davies,et al.  Human dystrophin expression in mdx mice after intramuscular injection of DNA constructs , 1991, Nature.

[49]  T. Partridge.  Invited review: Myoblast transfer: A possible therapy for inherited myopathies? , 1991, Muscle & nerve.

[50]  J. Huard,et al.  Dystrophin expression in myotubes formed by the fusion of normal and dystrophic myoblasts , 1991, Muscle & nerve.

[51]  H. Jockusch,et al.  Decreased osmotic stability of dystrophin-less muscle cells from the mdx mouse , 1991, Nature.

[52]  J. Huard,et al.  A new technique to identify hybrid myotubes in vitro without culture fixation. , 1991, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[53]  E. Hoffman,et al.  Normal myogenic cells from newborn mice restore normal histology to degenerating muscles of the mdx mouse , 1990, The Journal of cell biology.

[54]  Simon C Watkins,et al.  Somatic reversion/suppression of the mouse mdx phenotype in vivo , 1990, Journal of the Neurological Sciences.

[55]  Y. Pouliot,et al.  Dystrophin is expressed in mdx skeletal muscle fibers after normal myoblast implantation. , 1989, The American journal of pathology.

[56]  M. Fardeau,et al.  Regeneration of skeletal muscle fibers from autologous satellite cells multiplied in vitro. An experimental model for testing cultured cell myogenicity , 1989, Muscle & nerve.

[57]  E A Barnard,et al.  The molecular basis of muscular dystrophy in the mdx mouse: a point mutation. , 1989, Science.

[58]  L. Kunkel,et al.  Conversion of mdx myofibres from dystrophin-negative to -positive by injection of normal myoblasts , 1989, Nature.

[59]  S. Dimauro,et al.  Duchenne muscular dystrophy: Deficiency of dystrophin at the muscle cell surface , 1988, Cell.

[60]  L. Larsson.  Immunocytochemistry: Theory and Practice , 1988 .

[61]  Hideo Sugita,et al.  Immunostaining of skeletal and cardiac muscle surface membrane with antibody against Duchenne muscular dystrophy peptide , 1988, Nature.

[62]  Simon C Watkins,et al.  Immunoelectron microscopic localization of dystrophin in myofibres , 1988, Nature.

[63]  R. Hodges,et al.  The Duchenne muscular dystrophy gene product is localized in sarcolemma of human skeletal muscle , 1988, Nature.

[64]  J. Sanes,et al.  Use of a recombinant retrovirus to study post‐implantation cell lineage in mouse embryos. , 1986, The EMBO journal.

[65]  K. Moore,et al.  X chromosome-linked muscular dystrophy (mdx) in the mouse. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[66]  H. Blau,et al.  Defective myoblasts identified in Duchenne muscular dystrophy. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[67]  Margaret A. Johnson,et al.  Pathological responses of rat skeletal muscle to a single subcutaneous injection of a toxin isolated from the venom of the Australian tiger snake, Notechis scutatus scutatus , 1975 .

[68]  Ice,et al.  MYOBLAST TRANSFER IN THE TREATMENT OF DUCHENNE ’ S MUSCULAR DYSTROPHY , 2000 .

[69]  P. Law,et al.  Histoincompatible myoblast injection improves muscle structure and function of dystrophic mice. , 1988, Transplantation proceedings.

[70]  T. Tsukahara,et al.  Negative immunostaining of Duchenne muscular dystrophy(DMD) and mdx muscle surface membrane with antibody against synthetic peptide fragment predicted from DMD cDNA. , 1988 .

[71]  Eric P. Hoffman,et al.  Dystrophin: The protein product of the duchenne muscular dystrophy locus , 1987, Cell.